natgillin/translations-raw huggingface dataset:
Regarding safety, Incresync's safety profile was consistent with that seen with the individual components. 
V zvezi z varnostjo zdravila Incresync je njegov varnostni profil skladen s profilom posameznih učinkovin.
Alogliptin does not work when the blood glucose is low. 
Alogliptin ne deluje, če je raven glukoze v krvi nizka.
HbA1c levels give an indication of how well the blood glucose is controlled. 
Vrednosti HbA1c kažejo, kako dobro je uravnavana glukoza v krvi.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Incresync, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Incresync vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
In both studies, the main measure of effectiveness was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached. 
V obeh študijah je bilo glavno merilo učinkovitosti sprememba vrednosti glikoziliranega hemoglobina (HbA1c), tj. deleža hemoglobina v krvi, vezanega na glukozo.
• together with metformin, in patients who are not satisfactorily controlled with a combination of pioglitazone and metformin. 
• skupaj z metforminom pri bolnikih, pri katerih sladkorna bolezen ni zadovoljivo urejena s kombinacijo pioglitazona in metformina.
The CHMP therefore considered that the combination of alogliptin and pioglitazone in Incresync is of benefit to patients. 
Zato je CHMP menil, da je kombinacija alogliptina in pioglitazona v zdravilu Incresync koristna za bolnike.
• in patients who are not satisfactorily controlled with pioglitazone alone, and who cannot be treated with metformin (another diabetes medicine); 
• pri bolnikih, pri katerih sladkorna bolezen ni zadovoljivo urejena samo s pioglitazonom in je ni mogoče zdraviti z metforminom (drugim zdravilom za zdravljenje sladkorne bolezni);
Alogliptin is licensed in the EU as Vipidia. 
Alogliptin je v EU odobren kot zdravilo Vipidia.
Incresync can also be used as a replacement tablet (supplying both alogliptin and pioglitazone) in patients who are already being treated with alogliptin and pioglitazone given separately. 
Zdravilo Incresync se lahko uporablja tudi kot nadomestna tableta (ki zagotavlja tako alogliptin kot pioglitazon) pri bolnikih, ki že jemljejo ločene tablete alogliptina in pioglitazona.
In the other study the effects of adding alogliptin to existing treatment with pioglitazone and metformin was compared with increasing the doses of pioglitazone. 
V drugi študiji so učinke dodajanja alogliptina k obstoječemu zdravljenju s pioglitazonom in metforminom primerjali s povečevanjem odmerkov pioglitazona.
For practical information about using Incresync, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Incresync naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
It is used as an addition to diet and exercise in adults with type 2 diabetes to improve the control of blood glucose (sugar) levels: 
Uporablja se kot dodatek k dieti in telesni vadbi pri odraslih bolnikih s sladkorno boleznijo tipa 2 za izboljšanje uravnavanja ravni glukoze (sladkorja) v krvi:
For more information about treatment with Incresync, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Incresync preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Both studies showed that the combination of active substances in Incresync could produce a small but clinically relevant improvement in HbA1c. 
Obe študiji sta pokazali, da je kombinacija zdravilnih učinkovin v zdravilu Incresync povzročila majhno, vendar statistično pomembno znižanje vrednosti HbA1c.
Together, these processes reduce blood glucose levels and help to control type-2 diabetes. 
Ti procesi skupaj znižujejo raven glukoze v krvi in prispevajo k nadzoru sladkorne bolezni tipa 2.
For the full list of all side effects reported with Incresync, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Incresync, glejte navodilo za uporabo.
The active substances in Incresync, alogliptin and pioglitazone, work in different ways to help correct this. 
Zdravilni učinkovini zdravila Incresync, alogliptin in pioglitazon, na različne načine pomagata odpraviti to težavo.
By blocking the breakdown of Incretin hormones in the blood, alogliptin prolongs their action in stimulating the pancreas to produce more insulin when blood glucose levels are high. 
Z zaviranjem razgradnje inkretinov v krvi alogliptin podaljša čas njihovega delovanja in tako spodbuja trebušno slinavko, da tvori več insulina, kadar je raven glukoze v krvi visoka.
If patients were previously taking pioglitazone alone, the strength of Incresync that provides the same dose of pioglitazone should be used. 
Če so bolniki prej jemali samo pioglitazon, je treba uporabiti jakost zdravila Incresync, ki vsebuje enak odmerek pioglitazona.
Incresync is a diabetes medicine containing the active substances alogliptin and pioglitazone. 
Incresync je zdravilo za zdravljenje sladkorne bolezni, ki vsebuje zdravilni učinkovini alogliptin in pioglitazon.
One of the studies compared the effects of alogliptin with placebo (a dummy treatment) when used as an add-on to existing treatment with pioglitazone (the same combination as in Incresync), with or without metformin or another diabetes medicine. 
V eni od študij so primerjali učinke alogliptina in placeba (zdravila brez zdravilne učinkovine), ki so ju dodajali obstoječemu zdravljenju s pioglitazonom (enaka kombinacija kot v zdravilu Incresync), z metforminom ali drugim zdravilom za zdravljenje sladkorne bolezni ali brez njega.
As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type-2 diabetes. 
Zaradi delovanja obeh zdravilnih učinkovin se raven glukoze v krvi zniža, kar prispeva k nadzoru sladkorne bolezni tipa 2.
How is Incresync used? 
Kako se zdravilo Incresync uporablja?
The CHMP considered that adding alogliptin to existing treatment with pioglitazone with or without metformin had shown to produce modest but clinically relevant improvements in HbA1c. 
Menil je, da je bilo dokazano, da je alogliptin kot dodatek k obstoječemu zdravljenju s pioglitazonom, z metforminom ali brez njega, povzročil majhno, vendar klinično pomembno znižanje vrednosti HbA1c.
When added to pioglitazone, the improvement was a fall of 0.47% at a dose of alogliptin of 12.5 mg, and 0.61% for alogliptin 25 mg. Incresync was at least as effective as pioglitazone and metformin in reducing HbA1c. 
Alogliptin, ki so ga dodajali pioglitazonu, je pri odmerku 12,5 mg znižal vrednosti za 0,47 %, pri odmerku 25 mg pa za 0,61 %.
If patients were previously taking pioglitazone and alogliptin separately, Incresync should be used in a strength that continues to provide the same doses. 
Če so bolniki prej ločeno jemali pioglitazon in alogliptin, je treba uporabiti tako jakost zdravila
How does Incresync work? 
Kako zdravilo Incresync deluje?
Alogliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. 
S povišanjem ravni insulina in znižanjem ravni hormona glukagona alogliptin zmanjša tudi količino glukoze, ki nastaja v jetrih.
Date of first authorisation: 11 January 2017 
Datum prve odobritve: 11. januar 2017
Distributor: XXXXXXXXXXX 
Distributer: XXXXXXXXXXX
Do not repeat this before each daily injection, otherwise you will not have enough Movymia for 28 days. 
Ne ponovite tega pred vsakodnevnim injiciranjem, saj tako ne boste imeli dovolj zdravila Movymia za 28 dni.
The Movymia Pen has a service life of two years. 
Movymia Pen ima življenjsko dobo dveh let.
• Do not use your Movymia Pen if it is damaged or if you have any doubts about its correct functioning. 
• Ne uporabljajte svojega Movymia Pen, če je poškodovan, ali če imate kakršne koli dvome o njegovem pravilnem delovanju.
If no drops emerge, repeat step G until you see some drops. 
Če se kapljice ne pojavijo, ponavljajte korak G, dokler ne vidite nekaj kapljic.
Movymia can be given with or without food. 
Zdravilo Movymia se lahko daje s hrano ali brez nje.
Your doctor will advise you and decide how long you should be treated with Movymia. 
Vaš zdravnik vam bo svetoval in se odločil, kako dolgo se morate zdraviti z zdravilom Movymia.
The Movymia Pen can be disposed of according to the instructions of the local authorities. 
Movymia Pen lahko odstranite v skladu z navodili lokalnih organov.
Make sure that the two indicator stripes are aligned. 
Prepričajte se, da sta obe indikatorski črti poravnani.
Legal manufacturer: Ypsomed AG Brunnmattstrasse 6 3401 Burgdorf Switzerland 
Pravni proizvajalec: Ypsomed AG Brunnmattstrasse 6 3401 Burgdorf, Švica
• the pen being used with a medical device, accessories or consumables other than those recommended by XXXXXXXXXXX. 
• uporaba peresnika z medicinskimi pripomočki, dodatki ali potrošnim materialom, razen tistih, ki jih priporoča XXXXXXXXXXX.
The warranty covers manufacturing and material defects of your Movymia Pen for two years of use, from purchase. 
Garancija zajema napake pri izdelavi in materialne napake vašega Movymia Pen za dve leti uporabe, od nakupa.
The Movymia Pen must not be used by blind or visually impaired patients without help from a trained able-bodied person. 
Movymia Pen ne smejo uporabljati slepi ali slabovidni bolniki brez pomoči usposobljene osebe.
B: Remove the cartridge holder by turning it (bayonet coupling). 
B: Odstranite nosilec vložka tako, da ga zavrtite (bajonetni spoj).
Do not repeat the injection on the same day. 
Ne ponovite injiciranja isti dan.
Gyömrői út 19-21 1103 Budapest HUNGARY 
Gyömrői út 19-21. 1103 Budimpešta Madžarska
Follow the instructions given in the table if you have any questions regarding the use of Movymia Pen: 
Upoštevajte navodila v tabeli, če imate kakršna koli vprašanja glede uporabe Movymia Pen:
Teriparatide has no or negligible influence on the ability to drive and use machines. 
Zdravilo Teriparatid nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
The Movymia Pen can be used by self-injecting patients above the age of 18 years, healthcare professionals or third parties such as, for instance, adult relatives. 
Movymia Pen lahko uporabljajo za samoinjiciranje bolniki starejši od 18 let, zdravstveni delavci ali druge osebe, kot na primer odrasli sorodniki.
Do not use Movymia: 
Ne uporabljajte zdravila Movymia:
Inject Movymia each day for as long as your doctor prescribes it for you. 
Zdravilo Movymia si vbrizgajte vsak dan, tako dolgo, kolikor vam vaš zdravnik predpiše.
d p≤0.025 compared with placebo. 
p ≤ 0,025 v primerjavi s placebom
Your doctor may advise you to take Movymia with calcium and vitamin D. Your doctor will tell you how much you should take each day. 
Vaš zdravnik vam bo morda ob uporabi zdravila Movymia svetoval jemanje kalcija in vitamina D. Povedal vam bo tudi, kolikšen odmerek vzemite vsak dan.
Movymia may increase calcium in your blood or urine. 
Zdravilo Movymia lahko zviša količino kalcija v vaši krvi ali urinu.
Needle is broken/curved/kinked. 
Igla je zlomljena/ukrivljena/upognjena.
Never immerse the Movymia Pen in water, as this could damage the pen. 
Nikoli ne potopite peresnika Movymia v vodo, saj bi to lahko poškodovalo peresnik.
What Movymia is and what it is used for 
Kaj je zdravilo Movymia in za kaj ga uporabljamo
Children and adolescents Movymia should not be used in children and adolescents (aged less than 18 years). 
Otroci in mladostniki Zdravila Movymia se ne sme uporabljati pri otrocih in mladostnikih (mlajših od 18 let).
If you have any questions concerning the use of the Movymia Pen, contact our customer service at any time. 
Če imate kakršna koli vprašanja o uporabi Movymia Pen, se kadar koli obrnite na našo podporo uporabnikom.
Manufacturer Gedeon Richter Plc. 
Izdelovalec Gedeon Richter Plc.
Fracture incidence in postmenopausal women 
Incidenca zlomov pri ženskah po menopavzi
Subcutaneous use {1x} SC 
subkutana uporaba {1x} s.c.
• Do not remove the cartridge from the Movymia Pen before it is empty. 
• Ne odstranite vložka iz Movymia Pen preden se izprazni.
Paediatric population and young adults with open epiphyses The safety and efficacy of teriparatide in children and adolescents less than 18 years have not been established. 
Pediatrična populacija in mladi odrasli z odprtimi epifizami Varnost in učinkovitost teriparatida pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
Overdose experience based on post-marketing spontaneous reports In post-marketing spontaneous reports, there have been cases of medication error where the entire contents (up to 800 micrograms) of a teriparatide pen have been administered as a single dose. 
Izkušnje s prevelikim odmerjanjem na podlagi spontanih poročil po uvedbi zdravila na trg V spontanih poročilih po uvedbi zdravila na trg so poročali o primerih napačnega odmerjanja, ko so dali vso vsebino (do 800 mikrogramov) peresnika s teriparatidom kot enkratni odmerek.
Do not use your Movymia Pen to inject any other medicine (e.g. insulin). 
Ne uporabljajte svojega peresnika Movymia Pen za injiciranje drugih zdravil (npr. insulina).
Do not use Movymia if it is, or has been, frozen. 
Zdravila Movymia ne uporabite, če je, ali če je bilo zamrznjeno.
The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (≥1/10,000 to 
Za klasifikacijo neželenih reakcij smo uporabili naslednji dogovor: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100) in redko (≥ 1/10.000 do < 1/1.000).
Other medicines and Movymia 
Druga zdravila in zdravilo Movymia
The most common side effects are pain in limb (which may affect more than 1 in 10 people). 
Najpogostejši neželeni učinki so bolečine v okončinah (pojavijo se lahko pri več kot 1 od 10 bolnikov).
F: Attach a new pen needle as follows: 
F: Novo iglo peresnika pritrdite na naslednji način:
The total duration of treatment with Movymia should not exceed 24 months. 
Celotno trajanje zdravljenja z zdravilom Movymia ne sme biti daljše od 24 mesecev.
Some patients get dizzy or get a fast heartbeat after the first few doses of Movymia. 
Nekateri bolniki postanejo omotični ali imajo po prvih nekaj odmerkih zdravila Movymia hitrejši utrip srca.
What you need to know before you use Movymia 
Kaj morate vedeti, preden boste uporabili zdravilo Movymia
For the correct use of this medicine it is very important to closely follow the detailed Instructions for Use of your pen which are provided with the pen. 
Za pravilno uporabo tega zdravila je zelo pomembno, da natančno upoštevate podrobna Navodila za uporabo vašega peresnika, ki so priložena peresniku.
Consult your doctor in the case of hearing or handling problems. 
Posvetujte se s svojim zdravnikom v primeru težav s sluhom ali težav z uporabo peresnika.
Injecting Movymia - Before you inject Movymia, clean your skin where you intend to inject (thigh or abdomen) as instructed by your doctor. 
Injiciranje zdravila Movymia - Pred injiciranjem zdravila Movymia očistite kožo na mestu, kamor si nameravate injicirati zdravilo (stegno ali trebuh) po navodilih svojega zdravnika.
• if you have continuing nausea, vomiting, constipation, low energy, or muscle weakness. 
• če vas nenehno sili na bruhanje ali bruhate, imate zaprtje, pomanjkanje energije ali mišično šibkost.
The pen needles must be used only once and the Movymia cartridge must be used by one person only. 
Igle za peresnike se lahko uporabi samo enkrat in vložek Movymia mora uporabljati samo ena oseba.
• Re-attach the pen cap after each use. 
• Ponovno pritrdite pokrovček peresnika po vsaki uporabi.
• Store your Movymia Pen, cartridges and pen needles out of reach of children. 
• Shranjujte vaš Movymia Pen, vložke in igle peresnika izven dosega otrok.
If you are considering stopping Movymia treatment, please discuss this with your doctor. 
Če razmišljate o prenehanju jemanja zdravila Movymia, se o tem posvetujte s svojim zdravnikom.
680 subjects were randomised to teriparatide and 680 subjects were randomised to oral risedronate 35 mg/week. 
680 bolnic je bilo randomiziranih v skupino s teriparatidom, 680 bolnic pa je bilo randomiziranih v skupino s peroralnim rizedronatom 35 mg/teden.
Pregnancy Movymia is contraindicated for use during pregnancy (see section 4.3). 
Nosečnost Zdravilo Movymia je med nosečnostjo kontraindicirano (glejte poglavje 4.3).
• Ypsomed mylife Clickfine 29 to 31 gauge (diameter 0.25 - 0.33 mm) and 12, 10, 8 or 6 mm length 
• Ypsomed mylife Clickfine 29 do 31G (premer 0.25 - 0.33 mm) in 12, 10, 8 ali 6 mm dolžine
• BD Micro-Fine Ultra needles 29 to 31 gauge (diameter 0.25 - 0.33 mm) and 12.7, 8 or 5 mm length Pen needles from other manufacturers can be used according to their stated compatibility details. 
• BD Micro-Fine Ultra igle 29 do 31G (premer 0.25 - 0.33 mm) in 12.7, 8 ali 5 mm dolžine Igle za peresnike drugih proizvajalcev se lahko uporabljajo v skladu z njihovimi navedenimi podatki o združljivosti.
Storage and care of Movymia Pen 
Skladiščenje in skrb za Movymia Pen
Movymia is a biosimilar medicinal product. 
Zdravilo Movymia je podobno biološko zdravilo.
Store it in the cartridge sleeve during the whole 28-day treatment period. 
Shranjujte ga v ovitku vložka v celotnem 28-dnevnem obdobju zdravljenja.
You can use Movymia for up to 28 days after the first injection, as long as the cartridge/pen with the cartridge inserted is stored in a refrigerator (2 °C to 8 °C). 
Zdravilo Movymia lahko uporabljate do 28 dni po prvem injiciranju, če je vložek/peresnik z vstavljenim vložkom shranjen v hladilniku (pri temperaturi med 2 °C in 8 °C).
Marketing Authorisation Holder STADA Arzneimittel AG Stadastrasse 2-18 
Imetnik dovoljenja za promet z zdravilom STADA Arzneimittel AG Stadastrasse 2-18
The pen and injection needles are not included with Movymia. 
Peresnik in injekcijske igle niso priloženi zdravilu Movymia.
• Do not store the Movymia Pen with a needle attached as this may cause air bubbles to form in the cartridge. 
• Movymia Pen ne shranjujte s pritrjeno iglo, ker se lahko zaradi tega v vložku pojavijo zračni mehurčki.
Follow the instructions every time you insert a new Movymia cartridge into your Movymia Pen. 
Upoštevajte navodila vsakič, ko vstavite nov vložek Movymia v peresnik Movymia Pen.
At baseline, the postmenopausal women had a mean age of 61 years, mean lumbar spine BMD T score of −2.7, median prednisone equivalent dose of 7.5 mg/day, and 34% had one or more radiographic vertebral fractures; premenopausal women had a mean age of 37 years, mean lumbar spine BMD T score of −2.5, median prednisone equivalent dose of 10 mg/day, and 9% had one or more radiographic vertebral fractures; and men had a mean age of 57 years, mean lumbar spine BMD T score of −2.2, median prednisone equivalent dose of 10 mg/day, and 24% had one or more radiographic vertebral fractures. 
V osnovi so imele ženske po menopavzi povprečno starost 61 let, srednjo T-vrednost mineralne gostote kosti (BMD) ledvenega dela hrbtenice -2,7, srednji ustrezni odmerek prednizona 7,5 mg/dan in 34 % jih je imelo enega ali več radiografskih zlomov; ženske pred menopavzo so imele povprečno starost 37 let, srednjo T-vrednost mineralne gostote kosti (BMD) ledvenega dela hrbtenice -2,5, srednji ustrezni odmerek prednizona 10 mg/dan in 9 % jih je imelo enega ali več radiografskih zlomov; moški so imeli povprečno starost 57 let, srednjo T-vrednost mineralne gostote kosti (BMD) ledvenega dela hrbtenice -2,2, srednji ustrezni odmerek prednizona 10 mg/dan in 24 % jih je imelo enega ali več radiografskih zlomov.
Tilting the pen may result in bending or breaking of the needle. 
Z nagibanjem peresnika lahko pride do upogibanja ali zloma igle.
Movymia should not be used in growing adults. 
Zdravila Movymia se ne sme uporabljati pri odraslih v dobi rasti.
If the display still does not return to start position after injection, do not use this pen; contact customer service. 
Če se zaslon po injiciranju še vedno ne vrne v začetni položaj, tega peresnika ne uporabljajte; kontaktirajte podporo uporabnikom.
Do not use this pen; contact customer service. 
Ne uporabljajte tega peresnika; kontaktirajte podporo uporabnikom.
During dose dialling the pen does not provide an audible signal. 
Med izbiranjem odmerka peresnik ne oddaja zvočnega signala.
Movymia is indicated in adults. 
Zdravilo Movymia je indicirano pri odraslih.
Use your Movymia Pen only as prescribed by your doctor, in this instructions for use and the Movymia package leaflet. 
Uporabljajte svoj Movymia Pen le kot vam je predpisal vaš zdravnik, kot je opisano v teh navodilih za uporabo in kot je opisano v navodilu za uporabo zdravila Movymia.
• To set the fixed daily dose of 80 microliters, turn the dose knob clockwise until it stops and cannot be rotated any further. 
• Če želite nastaviti dnevni odmerek 80 mikrolitrov, obračajte gumb za odmerjanje v smeri urinega kazalca, dokler se ne ustavi in ga ne morete več obrniti.
{Displayed in case of 1x and 3x cartridges only. 
{Prikazano samo v primeru 1 ali 3 vložkov.
The efficacy of teriparatide in men and women (N=428) receiving sustained systemic glucocorticoid therapy (equivalent to 5 mg or greater of prednisone for at least 3 months) was demonstrated in the 18-month primary phase of a 36-month, randomised, double-blind, comparator-controlled study (alendronate 10 mg/day). 
Učinkovitost teriparatida pri moških in ženskah (N = 428), ki so prejemali podaljšano sistemsko glukokortikoidno terapijo (kar ustreza 5 mg ali več prednizona v najmanj 3 mesecih) so dokazali v 18-mesečni začetni fazi 36-mesečne, randomizirane, dvojno slepe, s primerjavo kontrolirane študije (alendronat 10 mg/dan).
• your Movymia Pen with inserted cartridge 
• vaš Movymia Pen z vstavljenim vložkom
Method of administration Movymia should be administered once daily by subcutaneous injection in the thigh or abdomen. 
Način uporabe Zdravilo Movymia se uporablja enkrat dnevno kot subkutana injekcija v stegno ali trebuh.
For the first doses, inject Movymia in a place where you can sit or lie down right away if you get dizzy. 
Prvih nekaj odmerkov injicirajte zdravilo Movymia na mestu, kjer se, če postanete omotični, lahko usedete ali takoj uležete.
What Movymia contains - The active substance is teriparatide. 
Kaj vsebuje zdravilo Movymia - Učinkovina je teriparatid.
A: Remove the pen cap. 
A: Odstranite pokrovček peresnika.
Contact customer service if the second needle cannot be attached. 
Obrnite se na podporo uporabnikom, če tudi druge igle ni mogoče pritrditi.
Pen preparation - First use/changing cartridges 
Priprava peresnika - Prva uporaba/zamenjava vložkov
Write down the first injection date of each new cartridge. 
Zapišite datum prvega injiciranja za vsak nov vložek.
This will keep the remaining Movymia sterile and prevent leaking from the pen. 
Na ta način bo preostala količina zdravila Movymia ostala sterilna, obenem pa boste preprečili iztekanje zdravila iz peresnika.
• using cartridges other than Movymia cartridges 
• uporabo ostalih vložkov razen vložkov Movymia
If you forget to use Movymia 
Če ste pozabili uporabiti zdravilo Movymia
• A damp cloth is sufficient to clean the Movymia Pen. 
• Za čiščenje peresnika Movymia je zadostna vlažna krpa.
Major non-vertebral fragility fractures c (hip, radius, humerus, ribs and pelvis) 
Večji nevretenčni zlomi zaradi krhkosti c (kolk, koželjnica, nadlahtnica, rebra in medenica)
Disposal of Movymia Pen and used accessories 
Odstranjevanje Movymia Pen in uporabljenih pripomočkov